ArticleMedicine2026
Serum uric acid to HDL-cholesterol ratio predicts all-cause mortality in cancer patients based on NHANES data.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the relationship between serum uric acid to high-density lipoprotein-cholesterol ratio (UHR) and all-cause mortality among US cancer patients. Data from the 2005 to 2018 National Health and Nutrition Examination Survey, linked to National Death Index records until December 31, 2019, are analyzed. To investigate the relationship between UHR and mortality, multivariate Cox proportional hazards models are utilized. Kaplan-Meier curves compare survival across UHR quartiles, while the restricted cubic spline approach evaluates dose-response relationships. Subgroup analyses consider age, gender, diabetes, hypertension, body mass index, and income-to-poverty ratio, with stratified analyses by cancer type. Two sensitivity analyses exclude participants under 65 and those with multiple cancers. During the 81.0-month follow-up period, the all-cause mortality rate is 15.6%. Cancer patients in the top quartile group have a significantly increased mortality risk (hazard ratio: 1.43, 95% confidence interval: 1.07-1.93). Kaplan-Meier survival analysis links higher UHR to reduced survival. This association is nonlinear and more pronounced in those aged ≥ 65, males, and individuals with diabetes or hypertension. Stratified analyses reveal a significant link in breast, colorectal, and prostate cancers. UHR may serve as a valuable predictor of all-cause mortality among individuals with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.